These results provide the feasibility of targeting both JAK2 and Lyn in treatment of F/P-positive CEL with imatinib-intolerance or IR, and also offer a new insight into the mechanism of F/P-driven CEL. Here, JAK2 is linked to Chronic Eosinophilic Leukemia, Not Otherwise Specified.